Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Anchor Investment Management LLC

Anchor Investment Management LLC lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,973 shares of the medical equipment provider’s stock after selling 1,250 shares during the quarter. Anchor Investment Management LLC’s holdings in Zimmer Biomet were worth $1,129,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ZBH. Ameriprise Financial Inc. grew its stake in Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after buying an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after buying an additional 1,488,918 shares during the last quarter. Nuveen LLC purchased a new position in Zimmer Biomet during the 1st quarter worth approximately $155,891,000. Nuveen Asset Management LLC grew its stake in Zimmer Biomet by 191.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider’s stock worth $146,763,000 after buying an additional 913,310 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Zimmer Biomet during the 1st quarter worth approximately $101,294,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.5%

Zimmer Biomet stock opened at $102.33 on Thursday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a market cap of $20.27 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.68. The stock’s 50 day moving average price is $99.06 and its 200 day moving average price is $99.63.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the previous year, the business earned $2.01 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Raymond James Financial raised their price target on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Royal Bank Of Canada lifted their target price on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Evercore ISI lowered their target price on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 8th. Finally, UBS Group lifted their target price on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research note on Friday, August 8th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $111.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.